AI for Clinical Trials & Pharma
Learn how AI accelerates drug development — from patient recruitment and trial design to pharmacovigilance and FDA compliance. Course with certificate — try 2 lessons free.
Clinical trials cost a median $708 million per approved drug. 90% of drugs that enter trials fail. And 80% of trials miss their enrollment deadlines.
AI is attacking every one of these problems. Insilico Medicine took a drug from concept to Phase I in 30 months — a process that typically takes 5 years. AI recruitment tools have nearly doubled enrollment rates. And AI-powered pharmacovigilance catches safety signals that humans miss.
This course shows you exactly how AI is reshaping drug development — from discovery through post-market surveillance — and what it means for everyone working in clinical research.
What You'll Learn
- Explain how AI compresses drug development timelines from 10-15 years to 3-6 years and where the biggest efficiency gains occur
- Evaluate AI patient recruitment tools that improve enrollment rates by up to 65% using EHR mining and NLP-powered matching
- Apply AI-driven protocol optimization techniques that reduce flawed trial designs and accelerate enrollment timelines
- Analyze synthetic control arms and real-world evidence frameworks accepted by FDA and EMA for regulatory submissions
- Assess AI pharmacovigilance systems that detect adverse drug reactions across EHRs, spontaneous reports, and social media
- Design an AI integration strategy for clinical trials that addresses FDA credibility requirements, algorithmic bias, and data privacy
After This Course, You Can
What You'll Build
Course Syllabus
Frequently Asked Questions
Who is this course for?
Clinical researchers, pharma professionals, CRO staff, regulatory affairs specialists, and anyone involved in drug development who wants to understand how AI is transforming clinical trials.
Do I need a science background?
Basic familiarity with clinical trial phases and drug development helps, but the course explains all concepts from the ground up. It's designed for intermediate learners.
Does this cover FDA regulations?
Yes. Lesson 7 covers the FDA's January 2025 draft guidance on AI for drug development, including the risk-based credibility framework and submission requirements.
How current is the content?
The course draws on 34 sources from 2024-2025, including the latest FDA guidance, Insilico Medicine's Phase 2a results, and the Recursion-Exscientia merger.
